Evotec SE (EVO)

Biotechnology · market cap $276M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Evotec SE (EVO) is a biotechnology company with approximately 4,788 employees and a market capitalization of roughly $455 million at a share price near $2.90. Its disclosed clinical pipeline centers on EVT 201, a Phase 2 asset targeting Sleep Initiation and Maintenance Disorders of unspecified mechanism. No near-term catalysts are currently scheduled, and key financial details including cash position, runway, and dilution history are not available in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
EVT 201	Phase 2	Sleep Initiation and Maintenance Disorders

Price & technical context

3-month

-40.0%

6-month

-31.6%

12-month

-51.7%

52-wk range

$1.53–$4.15

vs 50-day MA

-7.5%

vs 200-day MA

-36.9%

Realized vol

56.1%

Max drawdown

-72.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for EVO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.